Amanote Research
Register
Sign In
Pmu66 - Cost-Effectiveness Analysis of Ixekizumab Versus Secukinumab in Patients With Psoriatic Arthritis and Concomitant Moderate-To-Severe Psoriasis in Spain
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.1902
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
B Schweikert
CT Storck
M Núñez
T Dilla
S Hartz
C Sapin
Publisher
Elsevier BV
Related search
Pmu67 - Cost-Effectiveness Analysis of Ixekizumab Versus Secukinumab in Patients With Psoriatic Arthritis and Concomitant Moderate-To-Severe Psoriasis in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The Effect of Psoriatic Arthritis on Ixekizumab Clinical Outcomes in Moderate-To-Severe Psoriasis Patients: A Post Hoc Analysis
Journal of the American Academy of Dermatology
Dermatology
Cost-Effectiveness Analysis of Baricitinib Versus Adalimumab for the Treatment of Moderate-To-Severe Rheumatoid Arthritis in Spain
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Ixekizumab: Targeting Plaque Psoriasis and Psoriatic Arthritis
Prescriber
Pharmacology
Pms38 - Cost Effectiveness Analysis of Secukinumab Versus Ustekinumab for the Treatment of Psoriatic Arthritis in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Ixekizumab Efficacy and Safety in Moderate-To-Severe Genital Psoriasis
British Journal of Dermatology
Dermatology
Medicine
059 Ixekizumab Shows No Association With MACE in Patients With Moderate-To-Severe Psoriasis: An Integrated Safety Analysis of Clinical Trials
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology
Matching-Adjusted Indirect Comparison: Secukinumab Versus Infliximab in Biologic-Naive Patients With Psoriatic Arthritis
Journal of Comparative Effectiveness Research
Health Policy
540 Rapid Response in PASI, sPGA, and BSA Measures for Patients With Moderate-To-Severe Plaque Psoriasis With Ixekizumab
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology